Printer Friendly

MACRONEX APPOINTS TWO NEW MEMBERS TO SCIENTIFIC ADVISORY BOARD

 RESEARCH TRIANGLE PARK, N.C., May 20 /PRNewswire/ -- Macronex, Inc., today announced it has appointed Thomas Glenn, Ph.D., and Seth Rudnick, Ph.D., to its Scientific Advisory Board. Dr. Glenn is currently the president and COO of Phytopharmaceuticals and Dr. Rudnick is the chairman and CEO of CytoTherapeutics, Inc. Each appointee brings to Macronex more than 20 years experience in the development of pharmaceuticals.
 "We are pleased to have two individuals with vast and varied experience in the development of therapeutics join our board," said Dennis D. Burns, president and chief executive officer of Macronex. "Drs. Glenn and Rudnick's accomplishments in biotechnology pharmaceuticals and their present leadership positions will supply Macronex with the expertise needed to guide us through those formative years of development."
 Prior to joining Phytopharmaceuticals in 1991, Dr. Glenn held several senior scientific management positions in biotechnology and pharmaceutical companies. He was vice president of Pharmacology and senior director of Phamacological Sciences for Genentech, senior vice president, director of research for Ciba-Geigy and vice president of Pharmaceutical Development for Cytel. Dr. Glenn also served as chairman of the Department of Pharmacology at the University of Alabama College of Medicine. Dr. Glenn holds an M.S. and a Ph.D. from the University of Missouri.
 Before his appointment at CytoTherapeutics in 1991, Dr. Rudnick served as vice president and later, senior vice president of the R.W. Johnson Pharmaceutical Research Institute where he was responsible for all research and development activities. Previously, Dr. Rudnick was vice president of Biotech Product Development for Johnson & Johnson's Ortho Pharmaceutical Corporation. Additionally, Dr. Rudnick served as senior vice president for Pharmaceutical Development and vice president for Medical Research at Biogen Research Corp. as well as the director of Clinical Research at Schering Plough. Dr. Rudnick is an associate professor at Brown University and has held several positions at the University of North Carolina. He holds a B.A. from the University of Pennsylvania and an M.D. from the University of Virginia.
 Macronex, a biopharmaceutical discovery and development company based near Research Triangle Park, N.C., was founded in 1990 to exploit scientific advances made in the laboratories of its Duke University Medical Center-based founders. The company is developing therapeutics for acute and chronic inflammatory diseases.
 -0- 5/20/93
 /CONTACT: George Cianciolo, Ph.D., Executive Vice President, Research and Development, Macronex, 919-481-4390, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Macronex/


CO: Macronex, Inc. ST: North Carolina IN: MTC SU: PER

CM -- CH002 -- 0670 05/20/93 10:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1993
Words:424
Previous Article:DUKE POWER OFFERS LOW FINANCING FOR ENERGY EFFICIENCY
Next Article:PENN CENTRAL TO PUBLICLY OFFER TEJAS SHARES
Topics:


Related Articles
SCIOS-NOVA SENIOR SCIENTIST JOINS MACRONEX AS DIRECTOR OF CHEMISTRY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters